454 related articles for article (PubMed ID: 17370308)
1. Levodopa "drug holiday" with amantadine infusions as a treatment of complications in Parkinson's disease.
Koziorowski D; Friedman A
Mov Disord; 2007 May; 22(7):1033-6. PubMed ID: 17370308
[TBL] [Abstract][Full Text] [Related]
2. [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
Cersósimo MG; Scorticati MC; Micheli FE
Medicina (B Aires); 2000; 60(3):321-5. PubMed ID: 11050808
[TBL] [Abstract][Full Text] [Related]
3. Parkinson's disease in the elderly: current management strategies.
Aminoff MJ
Geriatrics; 1987 Jul; 42(7):31-7. PubMed ID: 3110015
[TBL] [Abstract][Full Text] [Related]
4. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
da Silva-Júnior FP; Braga-Neto P; Sueli Monte F; de Bruin VM
Parkinsonism Relat Disord; 2005 Nov; 11(7):449-52. PubMed ID: 16154788
[TBL] [Abstract][Full Text] [Related]
5. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.
Antonini A; Isaias IU; Canesi M; Zibetti M; Mancini F; Manfredi L; Dal Fante M; Lopiano L; Pezzoli G
Mov Disord; 2007 Jun; 22(8):1145-9. PubMed ID: 17661426
[TBL] [Abstract][Full Text] [Related]
6. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Parkinson Study Group CALM Cohort Investigators
Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
[TBL] [Abstract][Full Text] [Related]
7. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
[TBL] [Abstract][Full Text] [Related]
8. Long-term therapy of Parkinson's disease with amantadine, alone and combined with levodopa.
Zeldowicz LR; Hubermann J
Can Med Assoc J; 1973 Oct; 109(7):588-93. PubMed ID: 4582563
[TBL] [Abstract][Full Text] [Related]
9. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
10. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
11. 'Drug holidays' in the treatment of Parkinson's disease. A brief review.
Friedman JH
Arch Intern Med; 1985 May; 145(5):913-5. PubMed ID: 3888135
[TBL] [Abstract][Full Text] [Related]
12. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
[TBL] [Abstract][Full Text] [Related]
13. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
Manson AJ; Turner K; Lees AJ
Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
[TBL] [Abstract][Full Text] [Related]
14. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life.
Puente V; De Fabregues O; Oliveras C; Ribera G; Pont-Sunyer C; Vivanco R; Cucurella G; Giralt E; Delgado T; Garcia C; Seoane A; Campo R
Parkinsonism Relat Disord; 2010 Mar; 16(3):218-21. PubMed ID: 19762271
[TBL] [Abstract][Full Text] [Related]
15. Excellent response to apomorphine in Parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication.
Deutschländer A; Asmus F; Marelli E; Klopstock T; Gasser T; Bötzel K
Mov Disord; 2006 Sep; 21(9):1523-5. PubMed ID: 16755578
[TBL] [Abstract][Full Text] [Related]
16. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
[TBL] [Abstract][Full Text] [Related]
17. High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study.
Arnold G; Gasser T; Storch A; Lipp A; Kupsch A; Hundemer HP; Schwarz J
Arch Gerontol Geriatr; 2005; 41(3):239-53. PubMed ID: 16029905
[TBL] [Abstract][Full Text] [Related]
18. [Levodopa-induced psychosis in patients with idiopathic Parkinson disease].
García-Escrig M; Bermejo Pareja F; Fernández Ponsatí JT
Med Clin (Barc); 1999 Feb; 112(7):245-50. PubMed ID: 10220750
[TBL] [Abstract][Full Text] [Related]
19. [Perioperative management of a patient with Parkinson's disease with intravenous infusion of levodopa].
Mizuno J; Kato S; Watada M; Morita S
Masui; 2009 Oct; 58(10):1286-9. PubMed ID: 19860235
[TBL] [Abstract][Full Text] [Related]
20. Features associated with the development of hallucinations in Parkinson's disease.
Benbir G; Ozekmekçi S; Cinar M; Beskardes F; Apaydin H; Erginöz E
Acta Neurol Scand; 2006 Oct; 114(4):239-43. PubMed ID: 16942542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]